Compare Prologis Inc (PLD) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Prologis Inc vs 10X Genomics Inc — how do they compare? Prologis Inc trades at $129.16 (market cap $120.98B), while 10X Genomics Inc trades at $80.1 (market cap $9.92B). The key difference: Prologis Inc is far larger — about 12.2× 10X Genomics Inc's market cap, and Prologis Inc pays a 3.36% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Prologis Inc for 102 Days and 10X Genomics Inc for 92 Days on average.
| PLD | TXG | |
|---|---|---|
Market Cap | $120.98B | $9.92B |
Volume | 3,604,776 | 9,372,166 |
Sector | Real Estate | Health |
52-Week High | $149.96 | $97.74 |
52-Week Low | $111.23 | $11.48 |
Typical Hold Time | 102 Days | 92 Days |
Enterprise Value | $155.72B | $9.44B |
Dividend Yield | 3.36% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Prologis (PLD) trades at $129.29, up 0.47% today, with a bearish technical signal from moving averages but bullish oscillators. The company has consistently beaten earnings expectations in recent quarters, with Q3 2026 results pending. Revenue grew to $8.79B in 2025, and net income margin stands strong at 45.79%. Recent news highlights strong leasing activity and data center growth potential, though the stock faces near-term resistance near $129.
The outlook for PLD is positive, supported by robust fundamentals and analyst consensus favoring a buy rating with a $155.15 price target. Key opportunities include e-commerce and data center demand driving rent growth. Risks involve rising debt levels, with debt-to-asset ratio increasing to 37.2% in 2025, and broader REIT sector volatility amid interest rate concerns.
10x Genomics (TXG) trades at $77.28, down 4.19% on the day, amid a bearish technical signal. The company reported revenue of $642.82M in 2025, with a net loss of $43.54M, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights the launch of its Atera spatial biology platform and a patent victory, signaling innovation and market strength. Cash flow from operations improved to $136.05M in 2025, indicating better operational efficiency.
The outlook is cautiously optimistic, with strong product demand and improving margins offering upside potential. However, persistent losses, high valuation multiples, and competitive pressures present significant risks. Analyst consensus is mixed, with a $74.30 price target slightly below the current price, reflecting uncertainty about near-term profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Prologis Inc
Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $70 billion of third-party AUM. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.
Read more on PLD →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
